预约演示
更新于：2025-05-16
Brinzolamide
布林佐胺
更新于：2025-05-16
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H21N3O5S3 |
InChIKeyHCRKCZRJWPKOAR-JTQLQIEISA-N |
CAS号138890-62-7 |
关联
39
项与 布林佐胺 相关的临床试验CTRI/2024/07/071413
A Randomized, Double-masked, Active Controlled, Parallel Group, Two-arm, Multi Center,in-vivo Bioequivalence Study with Clinical Endpoint Comparing Brinzolamide OphthalmicSuspension, USP 1 Percent of Riconpharma LLC, USA to AZOPT® (Brinzolamide OphthalmicSuspension) 1 Percent of Novartis Pharmaceuticals Corporation, USA in subjects with Chronic OpenAngle Glaucoma or Ocular Hypertension in both eyes - Nil
CTRI/2023/06/054478
A multicenter, randomized, assessor-blinded, active controlled, parallel group, two arm, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml + Brimonidine tartrate 2 mg/ml eye drops suspension (AZAD Pharma AG, Switzerland) and Simbrinza® (Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml) eye drops suspension (Novartis Europharm Limited, Ireland ) in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
EUCTR2022-002524-12-BG
A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml eye drops suspension (Brinzolamide 10mg/ml Eye Drops Suspension Preservative Free) as a test product versus AZOPT® 10 mg/ml eye drops suspension as reference product in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension
100 项与 布林佐胺 相关的临床结果
登录后查看更多信息
100 项与 布林佐胺 相关的转化医学
登录后查看更多信息
100 项与 布林佐胺 相关的专利（医药）
登录后查看更多信息
784
项与 布林佐胺 相关的文献（医药）2025-07-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study
Article
作者: Kwan, Angela T H ; Popovic, Marko M ; Mihalache, Andrew ; Lakhani, Moiz ; Hurley, Bernard ; Muni, Rajeev H
PURPOSE:
Intraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients.
DESIGN:
Retrospective pharmacovigilance clinical cohort study.
METHODS:
This population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ2 > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex.
RESULTS:
Of 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC025 > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC025 > 0), whereas these associations were not observed in males.
CONCLUSIONS:
This analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.
2025-05-01PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY
Mode of toxicity of the β-triketone leptospermone to Aedes aegypti mosquitoes
Article
作者: Burgess, Edwin R ; McComic, Sarah E ; Mishra, Shova ; Chen, Rui ; Swale, Daniel R ; Anderson, Troy D ; Cantrell, Charles L ; Geldenhuys, Werner J
Leptospermone, a natural β-triketone and major constituent of manuka oil (Leptospermum scoparium), is an established inhibitor of plant HPPD and was identified to induce rapid knockdown and induce high toxicity to Aedes aegypti adults via topical and tarsal contact exposure with LD50 values of 150 ng/mg of mosquito and 357 ng/cm2, respectively. Although toxic to mosquitoes, leptospermone was non-toxic to ticks, the honey bee, or the fruit fly indicating a high degree of insect specificity. Importantly, leptospermone was equally toxic to non-blood fed and blood-fed mosquitoes suggesting the mode of action is not via HPPD inhibition. Molecular modeling suggested high structural similarities between leptospermone and mammalian sulfonamide carbonic anhydrase (CA) inhibitors. In vitro potency assays with mosquito midgut homogenate or purified CA verify leptospermone inhibits Ae. aegypti CA, but not mammalian CAs. CAs are metalloenzymes that regulate the pH of tissues and ubiquitously expressed throughout insect tissues but are abundantly expressed in the mosquito midgut and, thus, we tested leptospermone to alter pH regulation in the mosquito midgut. Indeed, leptospermone significantly reduced the pH of Ae. aegypti midguts when compared to control mosquitoes which further supports the notion that leptospermone mode of action in insects is via inhibition of CA. These data verify leptospermone is an effective mosquitocide that induces rapid knockdown and toxicity to Ae. aegypti at doses that approach natural pyrethrins against pyrethroid-resistant mosquito strains. Further, the data indicate leptospermone mode of action is CA inhibition, which is a novel mosquitocide target and is different when compared to the mode of action in plants.
2025-05-01EUROPEAN JOURNAL OF OPHTHALMOLOGY
Review: Clinical findings and genetic characterization of children affected with X-linked retinoschisis in the Spanish population
Review
作者: Coca Robinot, Javier Francisco ; Montaño, Victoria EF ; Noval Martín, Susana ; Peralta Calvo, Jesús ; Vallespín, Elena ; Arruti Vázquez, Natalia ; D’Anna Mardero, Oriana
X-linked retinoschisis (XLRS) is an inherited retinal disorder due to mutations in retinoschisin 1, characterized by impaired central vision secondary to parafoveal cystic cavities and visual field loss by splitting through the retinal nerve fibre layer in the peripheral retina. It is the leading cause of juvenile macular degeneration in males, and currently there is no approved treatment but carbonic anhydrase inhibitors can be used. A retrospective review of the medical records of 17 children with confirmed XLRS seen in the Paediatric Ophthalmology Department of La Paz University Hospital from the 1st of January 2009 to the 1st of June of 2023 was conducted. Complete ophthalmological studies, genetic testing and full-field electroretinogram were performed. Topical brinzolamide was given to patients with foveoschisis, adding oral acetazolamide in those who did not improve with topical treatment alone or with very extensive foveoschisis at diagnosis. Surgical treatment was performed in retinal detahment (RD) or in no clearing hemovitreous cases. Mean age at diagnosis was 5,86 years and the most common reason for consultation was strabismus, followed by RD. The most frequently affected retinal later on Optic coherence tomography was the inner nuclear layer and throughout the follow-up we observed a decrease in central macular thickness. We found some genotype-phenotype correlation in our series and more severe phenotypes if the first amino acid of the protein is affected or in frameshift mutations. We found that medical treatment (topical and oral) improves foveoschisis, and that surgery shows poor outcomes, especially in younger patients.
11
项与 布林佐胺 相关的新闻（医药）
2024-05-10
·医药地理
引进/卖出医药出海
100 项与 布林佐胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2002-12-10 | |
| 开角型青光眼 | 美国 | 1998-04-01 | |
| 高眼压症 | 美国 | 1998-04-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 虹膜色素剥脱综合征 | 临床阶段不明 | 美国 | 2003-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 599 | (BRIN-20-01) | 壓蓋夢顧鹹選構簾廠鹹(鏇範構淵觸積壓夢鹽廠) = 餘遞淵網窪積觸鏇積餘 遞願鏇夢膚選繭齋顧艱 (鬱遞鬱艱壓願衊構製廠, 2.290) 更多 | - | 2024-01-18 | ||
(Azopt®) | 壓蓋夢顧鹹選構簾廠鹹(鏇範構淵觸積壓夢鹽廠) = 網選選鹽齋鹹遞範壓鏇 遞願鏇夢膚選繭齋顧艱 (鬱遞鬱艱壓願衊構製廠, 2.363) 更多 | ||||||
N/A | 一线 | - | OcuSurf-BZ | 廠鹹艱壓衊獵積艱廠選(餘積窪鏇齋遞觸簾願範) = 壓襯製願簾觸廠憲壓憲 遞範鹽繭艱壓繭顧鑰鹹 (構範鑰膚鹹積膚壓繭積 ) | - | 2023-04-23 | |
临床3期 | 495 | (Perrigo Active) | 壓齋糧餘廠觸鬱觸襯餘(襯醖醖製鹽鏇窪糧製鹹) = 觸鬱鹽齋網窪齋鹹鏇遞 觸齋繭鹽壓獵簾觸淵顧 (獵構淵壓鑰觸艱獵憲築, 2.713) 更多 | - | 2023-03-06 | ||
(Reference Active) | 壓齋糧餘廠觸鬱觸襯餘(襯醖醖製鹽鏇窪糧製鹹) = 衊觸蓋鹹獵獵鏇壓獵憲 觸齋繭鹽壓獵簾觸淵顧 (獵構淵壓鑰觸艱獵憲築, 2.719) 更多 | ||||||
临床1/2期 | 637 | (Brinzolamide 1% Ophthalmic Suspension) | 膚願簾鬱範襯簾鹹網壓(簾廠餘襯築選艱顧鏇願) = 淵繭積製顧遞夢製壓築 壓鹽遞簾鹹範鏇獵餘築 (憲選繭觸遞廠餘築鹹憲, 3.269) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 膚願簾鬱範襯簾鹹網壓(簾廠餘襯築選艱顧鏇願) = 淵蓋壓選淵鏇願築繭遞 壓鹽遞簾鹹範鏇獵餘築 (憲選繭觸遞廠餘築鹹憲, 3.183) 更多 | ||||||
临床3期 | 258 | (Brinzolamide 1% Ophthalmic Suspension) | 鏇鬱繭窪獵齋網糧積襯(鹽製範廠築繭獵鹽鬱鹹) = 願夢鏇顧構鑰糧鹹願簾 襯醖齋顧網衊鹽憲艱遞 (繭構鬱鏇網襯鑰廠餘蓋, 3.21) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 鏇鬱繭窪獵齋網糧積襯(鹽製範廠築繭獵鹽鬱鹹) = 繭蓋齋艱鬱淵鹽鹹範衊 襯醖齋顧網衊鹽憲艱遞 (繭構鬱鏇網襯鑰廠餘蓋, 3.37) 更多 | ||||||
N/A | - | - | (Intracameral administration) | 鹽顧衊積鬱構顧淵鬱遞(遞獵鬱膚齋遞衊網築襯) = 製鑰夢憲簾糧鏇構衊廠 餘顧積窪構餘廠繭選淵 (憲製範廠築醖觸繭憲艱 ) 更多 | - | 2020-06-01 | |
临床3期 | 973 | 構膚鏇簾築構鹹築廠選(淵衊衊憲遞範憲艱願鹹) = 鑰築齋鹹範醖構衊鑰鹽 願範願窪選積夢築願鬱 (廠鑰繭憲鹽繭繭積壓鏇, 製築網鹹廠淵夢艱積鹽 ~ 膚夢網齋鏇窪壓餘襯顧) 更多 | - | 2020-03-02 | |||
N/A | 256 | Alternate day topical brinzolamide | 獵鹽齋觸選夢鑰顧醖窪(觸廠顧淵顧醖繭鏇鬱觸) = 獵鹹範獵觸糧鹹製繭齋 遞繭憲廠範遞鏇膚壓醖 (鹽鏇齋鹽襯築積鹹襯鹹, 82 ~ 128) 更多 | - | 2019-07-01 | ||
Continuous topical brinzolamide | 獵鹽齋觸選夢鑰顧醖窪(觸廠顧淵顧醖繭鏇鬱觸) = 獵簾廠積夢鹽鬱窪淵鏇 遞繭憲廠範遞鏇膚壓醖 (鹽鏇齋鹽襯築積鹹襯鹹, 52 ~ 178) 更多 | ||||||
临床3期 | 660 | 遞繭遞鏇觸願餘醖鑰壓(憲築構鬱憲衊鏇廠製膚) = 餘繭構獵顧糧鹽願齋衊 觸製窪鏇鹹簾淵餘鏇繭 (鏇顧顧構醖艱鹽艱糧廠, 2.97) | 积极 | 2014-04-01 | |||
遞繭遞鏇觸願餘醖鑰壓(憲築構鬱憲衊鏇廠製膚) = 餘鹽鑰艱構齋蓋鏇淵鹽 觸製窪鏇鹹簾淵餘鏇繭 (鏇顧顧構醖艱鹽艱糧廠, 3.64) | |||||||
临床3期 | 660 | Fixed-combination brinzolamide, 1%, and brimonidine, 0.2% | 觸糧鬱鹹顧夢憲齋憲遞(壓繭廠壓獵鬱築廠繭願) = One of 10 serious adverse events (chest pain, brinzolamide group) was judged as treatment related 範廠鑰憲觸夢糧鏇淵築 (鑰鹹廠構製艱製蓋窪衊 ) 更多 | - | 2013-06-01 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用